Cargando…

Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib

Severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) has a high death rate in patients with comorbidities or in an immunocompromised state. We report a mild and attenuated SARS CoV-2 infection in a patient who is 17 months post stem cell transplantation and maintained on the JAK/STAT inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Foss, Francine M., Rubinowitz, Ami, Landry, Marie L., Isufi, Iris, Gowda, Lohith, Seropian, Stuart, Perreault, Sarah, Shenoi, Sheela V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Inc. 2020
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316063/ https://www.ncbi.nlm.nih.gov/pubmed/32727701 http://dx.doi.org/10.1016/j.clml.2020.06.014

Ejemplares similares

574. De-escalation of Broad Spectrum Antibiotics during Cytokine Release Syndrome with Haploidentical Hematopoietic Stem Cell Transplantation
por: Schiffer, Molly, et al.
Publicado: (2020)

577. Incidence and Outcomes of Positive Outpatient Surveillance Blood Cultures in Hematopoietic Stem Cell Transplant (HSCT) Patients with Graft Versus Host Disease (GvHD) On High Dose ≥ 0.5 mg/kg/day (HD) and Low Dose < 0.5mg/kg/day (LD) Steroid Therapy
por: Perreault, Sarah, et al.
Publicado: (2020)

2487. Vaccination Rates in Post-Transplant Hematopoietic Stem Cell Transplant (HSCT) Patients: Where Do We Stand?
por: Ahmad, Hiba, et al.
Publicado: (2018)

2694. Incidence of Pneumocytis jiroveci (PJP) Infection with 3-Month Prophylaxis of Aerosolized Pentamidine (AP) in Autologous Hematopoietic Stem Cell Transplantation (HSCT)
por: Perreault, Sarah, et al.
Publicado: (2019)

Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma
por: Potnis, Kunal C., et al.
Publicado: (2022)

P1381: DISTINCT CYTOKINE SIGNATURES OF IDECABTAGENE VICLEUCEL COMPARED TO AXICABTAGENE CILEUCEL AND LISOCABTAGENE MARALEUCEL
por: Mirza, Abu-Sayeef, et al.
Publicado: (2023)

P1385: DISTINCT RATES OF ICANS BUT SIMILAR CYTOKINE SIGNATURES BETWEEN TWO CD19-CAR T CELL THERAPIES: LISOCABTAGENE MARALEUCEL AND AXICABTAGENE CILOLEUCEL
por: Rasheed, Yusuf, et al.
Publicado: (2023)

Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups
por: Robin, Marie, et al.
Publicado: (2021)

Another tool against cytomegalovirus after allogeneic hematopoietic cell transplantation
por: Chen, George L., et al.
Publicado: (2023)

Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
por: Wu, Hengwei, et al.
Publicado: (2021)

Development of allogeneic hematopoietic stem cell transplantation in 2022: Regenerating “Groot” to heal the world
por: Lv, Meng, et al.
Publicado: (2023)

Do sophisticated models give the full picture of allogeneic hematopoietic stem cell transplantation effect?
por: Xu, Yujun, et al.
Publicado: (2022)

Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant
por: Cecchini, Michael, et al.
Publicado: (2015)

Is there a role for allogeneic hematopoietic stem cell transplantation for refractory follicular lymphoma?
por: Yang, Yang, et al.
Publicado: (2022)

Does ruxolitinib really prolong survival in individuals with myelofibrosis? The never-ending story
por: Barosi, Giovanni, et al.
Publicado: (2022)

Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT
por: Kröger, Nicolaus, et al.
Publicado: (2021)

COVID-19 in Hematopoietic Cell Transplant Recipients: A CIBMTR Study
por: Sharma, Akshay, et al.
Publicado: (2021)

Clinical Outcomes Associated With Respiratory Virus Detection Before Allogeneic Hematopoietic Stem Cell Transplant
por: Campbell, Angela P., et al.
Publicado: (2015)

Intestinal dysbiosis and allogeneic hematopoietic progenitor cell transplantation
por: Raghunathan, Vikram M., et al.
Publicado: (2016)

Relapse Following Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia Apparently Due to Somatic Cell Evolution via Epigenetic Variation and Immune Selection
por: Greenspan, Neil S.
Publicado: (2019)

A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation
por: Ljungman, Per, et al.
Publicado: (2020)

Salvage Therapy With Low-Dose Ruxolitinib Leads to a Significant Improvement in Bronchiolitis Obliterans Syndrome in Patients With cGVHD After Allogeneic Hematopoietic Stem Cell Transplantation
por: Zhao, Yanmin, et al.
Publicado: (2021)

RR6 prognostic model provides information about survival for myelofibrosis treated with ruxolitinib: validation in a real-life cohort
por: Scalzulli, Emilia, et al.
Publicado: (2022)

mRNA-1273 SARS-CoV-2 vaccine safety and COVID-19 risk perception in recently transplanted allogeneic hematopoietic stem cell transplant recipients
por: Albiol, Nil, et al.
Publicado: (2022)

The opposite impact of Janus kinase inhibitor Ruxolitinib on the function of bone marrow mesenchymal stem cells and immune cells in acute GVHD recipients
por: Zeng, Defu
Publicado: (2023)

Ruxolitinib attenuates secondary injury after traumatic spinal cord injury
por: Qian, Zhan-Yang, et al.
Publicado: (2022)

Ruxolitinib for myelofibrosis
por: GU, LIAN, et al.
Publicado: (2013)

Plasmacytoid precursor dendritic cells facilitate allogeneic hematopoietic stem cell engraftment
por: Fugier-Vivier, Isabelle J., et al.
Publicado: (2005)

Recurrent Subcutaneous Sweet's Disease in a Myelofibrosis Patient Treated with Ruxolitinib before Allogeneic Stem Cell Transplantation
por: Sakoda, Teppei, et al.
Publicado: (2017)

1092. Increased Risk of Serious Infections in Mantle Cell Lymphoma Versus Other Hematologic Malignancies in Patients on Ibrutinib
por: Holowka, Thomas, et al.
Publicado: (2020)

1095. Investigation of Risk Factors Associated with Serious Bacterial, Viral and Invasive Fungal Infections in Hematologic Patients on Ibrutinib
por: Holowka, Thomas, et al.
Publicado: (2020)

Ruxolitinib: Thrombocytopenia following compassionate use of ruxolitinib: 2 case reports
Publicado: (2022)

Donor‐derived M2 macrophages attenuate GVHD after allogeneic hematopoietic stem cell transplantation
por: Hanaki, Ryo, et al.
Publicado: (2021)

Allogenic Amniotic Tissue for Treatment of Knee and Hip Osteoarthritis
por: Gupta, Ashim
Publicado: (2022)

Expanding the use of allogeneic haematopoietic cell transplantation in dermatology
por: Bauer, J.W.
Publicado: (2021)

Colorectal Cancer Screening in the Novel Coronavirus Disease-2019 Era
por: Dekker, Evelien, et al.
Publicado: (2020)

Coronavirus disease 2019 pandemic and allogeneic hematopoietic stem cell transplantation: a single center reappraisal
por: Valentini, Caterina Giovanna, et al.
Publicado: (2021)

Ruxolitinib for essential thrombocythemia?
por: Bose, Prithviraj, et al.
Publicado: (2017)

Venetoclax or Ruxolitinib in Pre-Transplant Conditioning Lowers the Engraftment Barrier by Different Mechanisms in Allogeneic Stem Cell Transplant Recipients
por: Davis, Joanne E., et al.
Publicado: (2021)

P1308: RUXOLITINIB AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN APLASTIC ANEMIA PATIENTS
por: Zhang, Xiaoyu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_i138funfqkuanqum2cimcend9m